Name | Lenvatinib mesylate |
Description | Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities. |
In vitro | Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).?These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors[1]. |
Storage | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 16.67 mg/mL (31.87 mM), Sonication is recommended.
|
Keywords | VEGFR3 | VEGFR1 | VEGFR | Vascular endothelial growth factor receptor | SCFR | RET | Platelet-derived growth factor receptor | PDGFRβ | PDGFRα | PDGFR | Lenvatinib mesylate | Lenvatinib Mesylate | Lenvatinib | Inhibitor | inhibit | Fibroblast growth factor receptor | FGFR1 | FGFR | E-7080 | E7080 | E 7080 | cRET | c-Kit | cKit | CD117 |
Inhibitors Related | Gilteritinib | Amlexanox | Sunitinib | Nintedanib | Regorafenib monohydrate | Imatinib Mesylate | Sorafenib | Ferulic Acid | Regorafenib | Formononetin | Pazopanib | Axitinib |
Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |